Home
About
Overview
Sharing Data
ORCID
Help
History (1)
A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307.
A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. J Thorac Oncol. 2010 Oct; 5(10):1655-61.
View in:
PubMed
subject areas
Aged
Antineoplastic Agents
Benzenesulfonates
Extracellular Signal-Regulated MAP Kinases
Female
Humans
Male
Mesothelioma
Middle Aged
Neoplasm Staging
Niacinamide
Peritoneal Neoplasms
Phenylurea Compounds
Phosphorylation
Pleural Neoplasms
Pyridines
Survival Rate
Treatment Outcome
authors with profiles
Hedy Kindler
Everett E. Vokes